Biometrics: Announces

Showing posts with label Announces. Show all posts

Regulus Announces Key Goals Under its 'Clinical Map Initiative' for 2015

LA JOLLA, Calif., Jan. 8, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced key goals for 2015 under its 'Clinical Map Initiative' to advance its microRNA therapeutics portfolio and biomarkers platform.

"Regulus enters 2015 with the scientific and financial strength to realize the transformative potential of microRNAs. As such, we've set aggressive goals for the year focused on creating a clear path to value for what we believe to be our greatest opportunities," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "Under our 'Clinical Map Initiative', we are focusing our near term efforts on accelerating RG-101 for HCV with a Phase II dual-track clinical development strategy, while advancing our overall therapeutics pipeline and aligning our biomarker efforts to streamline our clinical development decisions."

Key Goals Under Regulus' 'Clinical Map Initiative' for 2015

'Clinical Map' of RG-101 for HCV Defined: Dual-Track Strategy Accelerates Phase II Development; Multiple Data Read-Outs in 2015. Following the favorable interim results reported in October 2014 from its ongoing clinical study, Regulus has accelerated development of RG-101, a wholly-owned, GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122") for the treatment of HCV. Regulus is pursuing a Phase II dual-track development strategy (i) to investigate RG-101 in combination with oral agents to potentially shorten treatment durations, optimize clinical outcomes and potentially improve responses in certain underserved HCV patient populations; and (ii) to investigate RG-101 further as a single agent to determine whether HCV viral cures are achievable with monotherapy treatment (single or multiple doses of RG-101). In the near term, Regulus expects to file both a Clinical Trial Application and an Investigational New Drug application for RG-101 with the goal to initiate the above described studies in Europe and the United States in the second quarter of 2015. Multiple Data Read-Outs for RG-101 in 2015. In early February 2015, Regulus expects to report new results from part IV of its ongoing clinical study of RG-101: viral load reduction and interim safety from the 4 mg/kg dose cohort (16 total HCV patients; 14 receiving a single administration of RG-101, 2 receiving placebo), as well as extended follow up results from the 2 mg/kg cohort. In the second quarter of 2015, Regulus expects to report full results from the ongoing study at a medical meeting. In the fourth quarter of 2015, Regulus plans to report viral load reduction and safety data from the Phase II program, as described above. 'Clinical Map' of RG-012 for Alport Syndrome Emerging; Near Term Focus on ATHENA Enrollment, Phase I Study to Initiate in 1H 2015. RG-012 is a single-stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of renal dysfunction in Alport syndrome patients. Alport syndrome is a life-threatening, genetic kidney disease driven by mutations in specific collagen. By inhibiting miR-21, which is highly overexpressed in animal models of Alport syndrome, RG-012 is intended to act by reducing the severity of fibrosis, which then may reduce the rate of decline of renal function in Alport syndrome patients. Near Term Efforts Focused on ATHENA. Regulus plans to focus its near term efforts on enrolling up to 120 Alport syndrome patients in its global ATHENA natural history of disease study, which is designed to characterize the natural decline of renal function (as measured by established renal markers) in Alport syndrome patients over time. The data from ATHENA should provide the clinical basis for the design of a Phase II proof-of-concept study to monitor the therapeutic effect of RG-012 on the decline in renal function in patients with Alport syndrome. The ATHENA study is being conducted at thirteen clinical sites worldwide, with multiple active sites in the United States, France and Germany, and additional sites anticipated to be active in Australia, Canada and other countries in Europe. In addition to enrolling patients in ATHENA, Regulus plans to initiate a Phase I study in the first half of 2015 to evaluate the safety and tolerability of RG-012 in healthy volunteers."2015 will be an important year for the advancement of our clinical portfolio, with key data read outs on the horizon for RG-101 and other programs," said Paul Grint, M.D., Chief Medical Officer of Regulus. "While aggressively moving forward with RG-101 this year, we also aim to expand our clinical pipeline to include opportunities in oncology and orphan diseases, such as Alport syndrome, where we believe we can build significant value for the portfolio."

microRNA Therapeutics Portfolio and Regulus microMarkersSM Goals for 2015
Advance microRNA Therapeutics Pipeline; Nominate At Least One Candidate for Clinical Development in 2015. Regulus continues to pursue several undisclosed microRNA targets, namely for oncology and orphan disease indications. In addition to its internal research efforts, Regulus aims to advance certain programs with its strategic alliance partners, microRNA-103/107 for the treatment of metabolic diseases and microRNA-19 for oncology indications with AstraZeneca, microRNA-221 and miR-21 for hepatocellular carcinoma and miR-21 for renal fibrosis (RG-012) with Sanofi. In 2015, Regulus expects to nominate at least one additional microRNA candidate for clinical development, either independently or with a partner.
Expand Regulus microMarkersSM Work to Support 'Clinical Map' of RG-101, RG-012 and Partners' Programs. Regulus' microMarkersSM division utilizes a highly reproducible, proprietary technology platform to extract, profile, and analyze microRNAs from small volumes of different bodily fluids to differentiate disease from healthy patient samples and to identify microRNAs as potential biomarkers for disease. Regulus microMarkersSM has profiled over 3,000 clinical samples in a wide variety of disease states and has formed a research collaboration with Biogen Idec, an additional large pharmaceutical partner (undisclosed), and multiple academic research institutions. To support the 'Clinical Map' of RG-101, Regulus microMarkersSM plans to profile serum samples from the healthy volunteers and HCV patients in the ongoing clinical study of RG-101 to identify potential microRNA signatures, which may aide in accurately predicting a patient's response to RG-101 therapy. Regulus microMarkersSM believes that it has identified a microRNA signature in urine that may discriminate mutant mice from wild type mice early in disease progression in a kidney fibrosis model. These findings suggest that profiling microRNAs in urine may be a useful biomarker approach to support the 'Clinical Map' of RG-012. As part of the ongoing ATHENA study, Regulus microMarkersSM plans to profile urine and blood samples from the Alport syndrome patients to potentially identify a clinically useful microRNA signature. To support its collaborators and academic research partners, Regulus microMarkersSM aims to utilize its robust technology platform to profile and analyze microRNAs in different bodily fluids including plasma, serum, whole blood, urine and cerebrospinal fluid. As part of its ongoing collaboration with Biogen Idec, Regulus microMarkersSM will profile whole blood samples of patients treated with a Biogen Idec multiple sclerosis therapy to identify potential microRNA signatures. "Regulus aims to pursue opportunities both internally and with our strategic partners where we can apply our oligonucleotide drug discovery and development expertise to validated microRNA targets," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus. "Specifically in 2015, our goal is to nominate at least one additional microRNA candidate for clinical development and expand our biomarkers work to support our clinical pipeline and our collaborators' programs."

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its domain dominant leadership in the microRNA field. Under its 'Clinical Map Initiative', Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. Regulus is also advancing several programs toward clinical development in orphan disease indications, oncology and fibrosis. Regulus' commitment to innovation has resulted in multiple peer-reviewed publications in notable scientific journals and has resulted in the formation of strategic alliances with AstraZeneca and Sanofi and a research collaboration with Biogen Idec focused on microRNA biomarkers. Regulus maintains its corporate headquarters in La Jolla, CA. For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected ability of Regulus to undertake certain activities and accomplish certain goals (including with respect to its 'Clinical Map Initiative' goals, including development and other activities related to RG-101 and RG-012 and with respect to the nomination of at least one microRNA candidate for clinical development in 2015), the projected timeline of clinical development activities, and expectations regarding future therapeutic and commercial potential of Regulus' business plans (including Regulus' expected future activities in 2015), technologies and intellectual property related to microRNA therapeutics and biomarkers being discovered and developed by Regulus. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE Regulus Therapeutics Inc.

HITLAB Announces Inaugural HITLAB Innovators Summit

NEW YORK, Oct. 30, 2014 /PRNewswire-USNewswire/ -- HITLABSM, a healthcare innovation and teaching lab, is pleased to announce its inaugural HITLAB Innovators SummitSM on December 1, 2014 at Columbia University's Low Library. HITLAB will partner with the Clinton Foundation's Health Matters Initiative, Saatchi & Saatchi Wellness, Blueprint Health, ProtoHack, Columbia Business School Alumni Club of New York, and Columbia Industrial Engineering and Operations Research, bringing together leaders in healthcare and technology to address the world's most significant healthcare needs through talks, workshops, demos, and an innovation challenge.

HITLAB Innovators Summit speakers will include Dr. Abdul El-Sayed from Columbia University, Dr. Robert Kelly from New York Presbyterian, Lexie Komisar from the Clinton Foundation, Sharon Suchotliff from Saatchi & Saatchi Wellness, and Josh Stein from AdhereTech, among others. As experts in medicine, technology, design, and policy, they will discuss how transformational technologies and healthcare delivery systems can be applied to global health issues such as chronic care management and access to life-saving technologies.

"We see amazing potential to advance health and wellness through technological and digital innovation, and the HITLAB Innovators Summit is a great opportunity to move this forward," said Lexie Komisar, Associate Director on Digital Health & Innovation for the Clinton Foundation's Health Matters Initiative.

The HITLAB Innovators Summit will also highlight the finalists from this year's HITLAB World CupSM competition, which awards significant funding and networking opportunities for the entrepreneurs and innovators who develop the best original solutions to global healthcare challenges. The first challenge in 2013 propelled winner AdhereTech to form customer relationships with top healthcare companies and raise $1.75 million in funding for its wireless smart pill bottle.

"Digital innovation has played a significant role in healthcare and will continue to shape and influence how people around the world approach health and wellness," said Sharon Suchotliff, VP, Director of Engagement Strategy for Saatchi & Saatchi Wellness. "The HITLAB Innovators Summit is a solutions-oriented event, and we look forward to collaborating and sharing ideas with its participants."

Additional information on the HITLAB Innovators Summit and registration details can be found at www.hitlabsummit.com. Sponsorship opportunities are available for interested healthcare leaders.

About the HITLAB Innovators SummitSM and HITLAB World CupSM
The HITLAB Innovators Summit brings together leaders from across the globe to share ideas and innovative approaches to addressing global health needs. As part of the daylong event, the HITLAB World Cup challenges entrepreneurs and innovators in healthcare and information technology to tackle global public health issues. www.hitlabsummit.com

About HITLAB
HITLAB is a healthcare innovation and teaching lab with a presence in the United States and India. We ideate, create, and evaluate innovative solutions to healthcare challenges for companies, foundations, multi-lateral agencies, and governments. In partnership with others whose missions align with ours, we independently, ethically, and efficiently design studies, programs, and products that improve healthcare access and quality throughout the world. www.hitlab.org

Media Contact:
Vivian Peng
HITLAB
212-543-0100
media@hitlab.org

FACEBOOK: http://www.facebook.com/hitlab.org

TWITTER: @HITLABNYC

SOURCE HITLAB

CLEAR Announces Expansion to McCarran International Airport in Las Vegas

NEW YORK, June 18, 2014 /PRNewswire/ -- CLEAR, a technology provider using advanced biometric identity verification to speed travelers through airport security, announced today it would launch its unique services Las Vegas's McCarran International Airport this summer.

"We are thrilled to be bringing CLEAR to Las Vegas. McCarran is the tenth airport offering our services," said CLEAR CEO Caryn Seidman Becker. "CLEAR and McCarran are dedicated to creating the safest and most efficient experience possible for travelers departing this world-renowned destination."

Certified by the Department of Homeland Security as Qualified Anti-Terrorism Technology, CLEAR members use their biometrics (fingerprint and iris) to verify their identity allowing them expedited security screening at major US airports across the country. At all of its locations CLEAR services are closely integrated with TSA's Pre-Check. Typical CLEAR members consistently get through airport checkpoints in less than 5 minutes. CLEAR anticipates launching dedicated members-only security lanes and enrollment kiosks in three of McCarran's checkpoints in mid-August 2014.

CLEAR membership is only $179 a year for unlimited use. Members can add their spouse or partner for an additional $50, and children under 18 are always free (no CLEAR card required) through the CLEAR lane. Military and corporate discounts are also available.

CLEAR's secure biometric technology is scalable for other uses and platforms, including stadiums, universities, municipal buildings and other venues seeking fast, effective and secure identity verification on a large scale.

For a demonstration on how CLEAR works, view this video: http://vimeo.com/53687250

ABOUT CLEAR

CLEAR currently operates at San Francisco, San Jose, Denver, Dallas-Fort Worth, Houston Bush, Houston Hobby, San Antonio, Orlando, and Westchester County Airport in New York. CLEAR has a growing base of over 300,000 loyal members nationwide and has been used almost two million times by travelers. CLEAR is currently expanding to bring its timesaving, secure biometric technology to airports around the country and is now integrated with TSA Pre-Check in all CLEAR locations. Enrollment is fast and easy and can be done at any of CLEAR's enrollment centers (http://clearme.com/enrollment-centers). For more information on how CLEAR is changing the way people travel, visit http://www.clearme.com.

SOURCE CLEAR

Digitus Biometrics announces compatibility with AMAG's Symmetry

Digitus Biometrics announces compatibility with AMAG's Symmetry. (PRNewsFoto/Digitus Biometrics)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SAVANNAH, Ga., June 12, 2014 /PRNewswire/ -- Working in conjunction with AMAG, Digitus Biometrics is proud to announce that its proprietary access management software, DAS-SQL, is now compatible with AMAG's Symmetry access control and video surveillance platform.

Data center security needs are evolving just as quickly as data potential and the tools being used to harness it. Many firms have already turned to Symmetry to meet their legacy card access control needs. Digitus offers a way to take server rack security to the next level, securing racks and cabinets with the swipe of a finger and integrating with preexisting Symmetry control software.

Digitus' patent-pending solutions optimize security using biometric technology and the latest in user monitoring and management. Firms will now be able to seamlessly migrate their user accounts and data to DAS-SQL, without having to re-enroll them. All user information will be shared between databases, simplifying management and control needs. Furthermore, all monitoring and maintenance needs to the systems will be able to be performed through a single interface, updating both platforms at once.

This compatibility will provide several distinct benefits to enterprises looking to optimize their data center security needs with biometrics. In addition to being able to build on their existing investment in building access control, companies will be able to secure server cabinets with the most secure access control platform on the planet. Firms will also receive guaranteed compliance with virtually all existing government and industry regulations, while managing these elements through a single point of administration for their building and cabinet access control systems.

Streamlined control over security management solutions will help enterprises boost workflow and facility protection needs around real-world operational demands, not idealistic views on access control. This optimization of identity and access will enhance processes to meet modern expectations for efficiency and privacy.

Media Contact:
Erin Fisher
Digitus Biometrics
Tele: (912) 231-8175

Logo - http://photos.prnewswire.com/prnh/20140611/117150

SOURCE Digitus Biometrics

reade more...

Marvin Test Solutions Announces completed shipment of USAF test PATS-70 joint ll Thunderbolt A-10/C

IRVINE, Calif., 03 of June of 2014/PRNewswire /-Marvin test solutions (formerly known as Geotest-Marvin test systems), a reliable supplier of test deployed around the world, innovative solutions for military, aerospace and manufacturing organizations, announced today the shipment on time and successful cost of its 85 armament Portable Test Set-70 (PATS-70) at Hill Air Force Base (AFB). Delivery of PATS-70 85 completes the current contract between Marvin test and the air force of United States (USAF) solutions. In addition, the USAF has deployed its first PATS-70 systems to support the 122 fighter wing based in Fort Wayne, Indiana

In 2013, the USAF awarded Marvin test solutions a $5.7 million a contract to create a platform for custom test that would accelerate the USAF fielding of the flightline PATS-70 test established by support of mission-critical to the modernized Thunderbolt A-10/C ll based on his experience in test flightline, Marvin test solutions was selected by the USAF to collaborate with test engineers at Hill AFB and develop an efficient, easy-to-use test set for the avionics recently digitized and updated electronic precision of weapon used in the A - 10 c.

At the core of the test of PATS-70 set is a customized version of the MTS-207, a flightline ultra heavy duty platform, based on PXI, portable. With the open architecture of the MTS-207, the USAF now has a flexible solution able to accommodate additional system test instrumentation as future testing needs evolve for the A-10/C, or even of other aircraft. The USAF completed the PATS-70 adding cables, test instrumentation, a test program software and user interface.

"The new PATS-70 test equipment complies with the need for the USAF to avionics flightline ultra heavy duty, high performance tests by leveraging the power of our compliant commercial, mil-spec chassis platform MTS-207," said Major General Steve Sargeant, USAF (Ret.) and CEO of Marvin Test Solutions. "We are pleased to have worked with the USAF personnel at Hill AFB to deliver these systems within your budget and timeline. Today, the solution of PATS-70 joins the long list of innovative equipment of test solutions Marvin currently deployed or ready to deploy from the factory and flightline deposit across multiple platforms, including the F-35, F-15, F-16, F-18, TA-50, f-50, F-5, Falcon and UASs. "

PATS-70 building with Marvin Test Solutions MTS-207

The PATS-70 is designed to be a system for measuring and testing reliable, modern flightline. A key feature is its ability to qualify fully digital avionics and electronic precision of weapon used in the A - 10 c. It is able to test several systems A-10/C, including:

Identification friend or foe anti-slip Alpha Mach fuel quantity stability augmentation system MIL-STD-1760 Protocol buses (MIL-STD-1553) for more information, readers can visit marvintest.com/PXI/Products/PXI-Chassis-3U-6U-Chassis-MTS-207.

About Marvin test solutions

Marvin Test Solutions is a company test and vertically integrated aerospace measurement that provides innovative solutions for factory, flightline, intermediate and Depot level applications. As a member of the Group of Marvin, an aerospace company awarded with a history of 50 years in the industries of Defense and Aerospace business, Marvin test solutions account with test systems deployed in support of the most important defense aircraft and munitions for use around the world. Marvin test solutions began in 1988 and continues to deliver proof of broad spectrum that make test, maintenance and logistics of the easiest mission-critical systems and solutions with lower total life cycle costs.

Communication/client media contact:Mike Dewey, MikeD@marvintest.com

Marvin source Test Solutions

NXT-ID, Inc. Announces Wocket™, its Next Generation Smart Wallet is now Available to Order - Put One in Your Pocket

SHELTON, Conn., May 28, 2014 /PRNewswire/ -- NXT-ID, Inc., (OTCQB: NXTD) (OTCBB: NXTD) a biometric authentication company focused on the growing m-commerce market, announces its next generation smart wallet, Wocket™ , designed to replace all the cards in your wallet is now available to order at www.wocketwallet.com . The Wocket retail price is $149.99.

Wocket™ is a smart wallet in the same vein as the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices. Wocket™ is a next generation smart wallet designed to protect your identity and replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.

Credit, debit, ATM, loyalty, gift, ID, membership, insurance, ticket, emergency, medical, business, contacts, coupon, and virtually any card can be protected on Wocket™. More than 10,000 cards, records, coupons, etc. and 100 voice commands can also be stored on Wocket™.

Gino Pereira, CEO of NXT-ID, Inc. said, "Today is a milestone for both NXT-ID and consumers that are concerned about the security of their wallet. We designed the Wocket specifically for the consumer of today that is still not willing to put all their payment and identity info on their smartphone. We believe Wocket is the solution that addresses security issues that consumers care about but still is convenient and easy to use."

The full Wocket product FAQ is available to consumers and media at
http://nxt-id.com/wocket-faq/

FAQ Highlights :

"What is Wocket ™?
Wocket™ is a smart wallet. Like the smart phone and smart watch, NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices.

"What does Wocket™ do?
Wocket™ locks all of your private information in an electronic "vault", where only an authenticated owner can authorize access to the data. Thus, you can "lock it with Wocket™ in your pocket", protecting your private information from unauthorized access.

"What makes Wocket™ smart?
Wocket™ smart wallet protects all of your private information inside an electronic vault while reducing the number of cards in your wallet. Dynamic pairing for authentication and encrypted data transfer with other secondary devices along with a plethora of new, innovative features makes Wocket™ the smartest wallet ever devised.

"How is Wocket™ different from other smart card solutions?
Wocket™ is not a smart card - it is a smart wallet. Thus, it can communicate with smart cards, but is not limited in the number, type, or method of communication of private information that typically restricts the use of a smart card. Furthermore, Wocket™ is not dependent on proximity or any other external factors to secure and choose soft-cards containing private information.

"How is Wocket™ different from other digital wallet solutions?
Rather than replace a wallet as many "digital wallet" technologies attempt to do, we chose to improve the wallet. Unlike other digital wallet solutions that depend on connectivity to choose a payment account, Wocket™ does not depend upon the cloud to select or make a payment.

"Does Wocket™ require another device, such as a cell phone?
No. Although Wocket™ does not require any other peripheral for security or "proximity sensing", Wocket™ can authenticate with secondary devices prior to transaction as an additional step in security as well as utilize a Wocket™ app on other devices to select or manage a soft-card, all without revealing private information.

"How do I access my private information?
A combination of biometrics, personal PIN or pattern provides multi-factor security for your Wocket™. Once Wocket™ verifies your identity, you can simply select whatever soft-card or information you want from the touch screen display, or in some configurations, your voice command.

"How many cards can be securely stored on a Wocket™?
Up to 10,000 cards, records, coupons, etc. and up to 100 voice commands can also be stored on Wocket™. More can be supported with optional additional memory.

About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/, http://www.wocketwallet.com/

NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/

Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Contact:

Corporate info: info@nxt-id.com

Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com

Media: 800 665-0411

SOURCE NXT-ID, Inc.

Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors

COMMACK, N.Y., July 2, 2014 /PRNewswire/ -- It is a great honor for Avery Biomedical Devices, Inc. (ABD) to announce the appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark E Ginsburg, M.D., to its Board of Directors.

Dr. Ginsburg, with over 34 years of experience, is currently practicing at two facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg has been implanting the Avery Breathing Pacemaker since the late 1980's and is considered an expert in the implantation of the Avery System. In addition, he has travelled the world to implant the Avery System in those patients who are unable to travel to the United States. He has published numerous scientific papers and books such as Lung Volume Reduction Surgery (LVRS) and Emphysema Treatments. In addition, he was lead investigator on several clinical trials.

Martin Dobelle, CEO, states, "We are humbled to have Dr. Ginsburg join our Board of Directors. His experience and expertise will be invaluable to the future growth of ABD."

Dr. Ginsburg states, "It is a privilege to serve on the Board of Directors of ABD. This company has served the world's need in diaphragm pacing. Exciting new products are under development in this and related arenas as well. I look forward to providing medical and surgical input to the Board."

ABOUT ABD

Avery Biomedical Devices, Inc. is a privately-held company located on Long Island, New York. It manufactures the Avery Breathing Pacemaker System: an implanted diaphragmatic pacemaker which is used to free many quadriplegics, central sleep apnea and diaphragm paralysis patients from mechanical ventilation. Most patients strongly prefer pacing to mechanical ventilation for reasons such as breathing and speech patterns, ease of eating and drinking and improved sense of smell. Since breathing pacemakers costs far less than mechanical ventilation and do not use percutaneous wire that pass through the skin (infection risk), it is the more prudent choice for life support.

The Avery Breathing Pacemaker is the only device of its kind with premarket approval from the USFDA and CE marking privileges under the European Active Implantable Medical Device Directive. Should you know of a patient with quadriplegia, central sleep apnea, diaphragm paralysis or another condition that may benefit from an Avery Breathing Pacemaker, please contact us.

CONTACT:
Martin D. Dobelle, CEO
631-864-1600
www.averybiomedical.com

SOURCE Avery Biomedical Devices, Inc.

RELATED LINKS
http://www.averybiomedical.com/

reade more...

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT

NEW YORK, June 27, 2014 /PRNewswire/ -- Pomerantz LLP has filed a class action lawsuit against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of its officers. The class action, filed in United States District Court, Middle District of Tennessee, Nashville Division, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Provectus securities between December 17, 2013 and May 22, 2014, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Provectus securities during the Class Period, you have until July 28, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Provectus is a development-stage biopharmaceutical company that focuses on developing pharmaceuticals for oncology and dermatology indications. The most important drug in the Company's pipeline is an oncology drug, PV-10, which is intended for the treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company utilized the services of paid stock promoters to inflate its share price; (ii) contrary to the Company's representations, preparations were not underway for a Phase 3 study for PV-10; and (iii) the Company improperly referred to PV-10 as obtaining a Breakthrough Therapy Designation ("BTD"), and otherwise implied that obtaining that status was inevitable.

On January 23, 2014, an article was published on TheStreet.com, accusing Provectus of artificially inflating the price of its stock by making false representations related to the commencement of Phase III clinical trials.

On this news, the Company's shares declined $3.35, or over 64%, to close at $21.87 on January 23, 2014.

Prior to May 20, 2014, the Company's website improperly described its PV-10 drug as a "breakthrough" drug for skin cancer, prior to the FDA's designation of the drug as such. On May 20, 2014, the Company updated its website and changed the description of PV-10 to "An Investigational Drug for Cancer" and included language clearly indicating that the drug was still awaiting BTD designation by the FDA.

On this news, Provectus securities declined $0.31 per share, or over 10%, to close at $2.70 per share on May 20, 2014.

On May 21, 2014, an article was published on SeekingAlpha.com alleging that the Company was tied to stock promoters that improperly marketed the Company's stock to unsophisticated retail investors, thus artificially inflating the price of the Company's shares. The article noted that trading in many of the other companies associated with these stock promoters was recently halted by the SEC. That same day, Provectus issued a press release refuting the allegations of the SeekingAlpha.com article. Provectus specifically noted that PV-10, its investigational metastatic melanoma therapy, had not failed the breakthrough therapy designation, but was awaiting a decision from the FDA as to the status of its request. Additionally, Provectus further denied any affiliation with stock promoters.

On this news, the Company's shares declined $0.46, or over 17%, to close at $2.24 on May 21, 2014.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

SOURCE Pomerantz LLP

RELATED LINKS
http://www.pomerantzlaw.com

reade more...

ETS Announces Advanced Biometric Voice Identification

ETS logo. (PRNewsFoto/Educational Testing Service)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";PRINCETON, N.J., May 8, 2014 /PRNewswire-USNewswire/ -- ETS today announced that a major new security enhancement, designed to reinforce the position of the company's TOEFL® Program as one of the most secure English-language tests in the world, has been rolled out worldwide. Biometric voice identification, one of the most significant advances in security in the testing sector in many years, was rolled out on February 8, 2014, in all 130 countries where students take the TOEFL test every year.

The TOEFL Program began piloting the software, which is designed to identify suspected impersonations, in May 2012, and the software has now been rolled out on a global scale as part of the screening process for all TOEFL test takers worldwide. ETS currently has a patent pending on the use of biometric voice identification software for this purpose, and the TOEFL test is the only English-proficiency test using this advanced security measure worldwide.

"The pilot phase of the biometric voice identification software proved it to be a major asset in identifying suspected impersonations and enabling ETS to cancel those scores before they were reported," commented David Hunt, Senior Vice President, Global Education and Workforce Division at ETS. "Security is a top priority at ETS, and we are proud to have this best-in-class security measure in place for our TOEFL test. Valid scores depend on secure administrations, and this powerful new tool will help to ensure just that."

The sophisticated biometrics voice identification software program was developed by a company that provides similar solutions for organizations in the banking, law enforcement and healthcare industries. ETS has also elevated the prominence of its whistleblower hotline to its home page to encourage anyone suspicious about fraudulent activity to make their concerns known to the company.

"The use of biometric voice identification technology is yet one more example of why we at The University of Texas at Austin consider the TOEFL iBT® the best measure of English proficiency available today," says Robert Watkins, Assistant Director Graduate and International Admissions Center at UTA.

ETS plans to extend biometric voice identification to cover the TOEIC® Program this year. More information regarding the TOEFL test's prevention and detection security processes is available at www.ets.org/toefl/institutions/about/security.

About ETS
At ETS, we advance quality and equity in education for people worldwide by creating assessments based on rigorous research. ETS serves individuals, educational institutions and government agencies by providing customized solutions for teacher certification, English language learning, and elementary, secondary and postsecondary education, and by conducting education research, analysis and policy studies. Founded as a nonprofit in 1947, ETS develops, administers and scores more than 50 million tests annually — including the TOEFL® and TOEIC® tests, the GRE ® tests and The Praxis Series® assessments — in more than 180 countries, at over 9,000 locations worldwide. www.ets.org

Logo - http://photos.prnewswire.com/prnh/20120110/DC33419LOGO

SOURCE Educational Testing Service

BioLife Solutions Announces First Quarter 2014 Results and Provides Business Update

BOTHELL, Wash., May 8, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced financial results for the first quarter of 2014 and a business update.

Q1 2014 Financial Summary

Core, proprietary product revenue increased by 47% over the first quarter of 2013, driven by continued adoption of HypoThermosol®, CryoStor® and BloodStor® in the biobanking, drug discovery, and regenerative medicine markets. Revenues were $2.1 million in the first quarter of 2014, a decline of 4% from the first quarter of 2013 which included one-time license revenue of $0.6 million. Excluding the impact of the license revenue in 2013, revenue from product sales increased 33% in the first quarter of 2014 compared with the first quarter of 2013. Gross margin was 44% in the first quarter of 2014 compared with 52% in the prior period. Excluding the impact of the license revenue that had no corresponding cost, gross margin in the first quarter of 2013 would have been 33%, with year-over-year improvement due to the strong growth in our high margin proprietary product revenue. Operating loss was $0.4 million compared to operating income of $0.2 million in the first quarter of 2013, which included the positive impact of one time license revenue of $0.6 million. Mike Rice, BioLife's President & CEO, said, "During the first quarter, in addition to again exceeding $1 million in sales of our proprietary clinical grade biopreservation media products, we completed a transformational set of financial transactions. We have substantially improved our balance sheet by eliminating all debt and closing a $15.4 million equity raisethat we believe will provide us with growth capital. We also completed a successful uplisting to the NASDAQ Capital Market®, which we believe will generate increased interest in our stock, allow us to attract more institutional investors and improve liquidity for shareholders. We are currently using some of this capital to expand our sales and marketing teams, attend additional scientific and trade conferences, and launch new organic and externally sourced products and services."

Other Significant Achievements for the First Quarter of 2014

The United States Patent and Trademark Office issued the Company a new patent on February 4, 2014. Patent number 8,642,255, titled "MATERIALS AND METHODS FOR HYPOTHERMIC COLLECTION OF WHOLE BLOOD", includes claims related to hypothermic preservation and storage of whole blood and blood components using the Company's HypoThermosol cell and tissue storage/shipping medium. We announced that Parcell Laboratories has adopted BioLife's CryoStor clinical grade cell and tissue freeze media for use in future clinical trials of Early Lineage Adult (ELA) stem cell therapies, for which Parcell holds an exclusive worldwide license. Adaptimmune Ltd adopted the Company's CryoStor clinical grade cell and tissue freeze media for use in Adaptimmune's current phase I/II clinical trial CT Antigen TCR-Engineered T Cells for Myeloma. With this announcement, Adaptimmune joined the growing list of BioLife customers developing adoptive immunotherapies for various cancers. The cancer immunotherapy field was selected by the editors of Science magazine as the Breakthrough of the Year for 2013.Contract Manufacturing Services Update and Estimated Impact to 2014 Results

We completed manufacturing products for the most recent purchase order from our contract manufacturing services customer in April 2014. Subsequently, we were informed that this customer does not intend to issue us any significant new purchase orders. We have not received any notice of termination of the manufacturing services agreement nor any breach of performance and we believe that we have met all of the performance requirements in the manufacturing services agreement with this customer.

Since the Company expects no further significant business from this customer and to enable the broadest operating freedom, on May 8, 2014, we provided this customer with notice of termination of the manufacturing services agreement dated December 22, 2011. The agreement's termination is anticipated to be effective on or about November 5, 2014, which is 180 days after the date of our notice. The agreement bars us from manufacturing or selling any solution that is approved for clinical use related to the storage and transportation of human organs for a period of two years after termination (the "tail period"). We do not expect the tail period restriction to affect our core proprietary business or our ability to pursue other non-conflicting contract manufacturing opportunities in any way.

We expect to record revenue of approximately $0.1 million related to the remainder of the most recent purchase order in the second quarter of 2014, and no further revenue subsequent to that. Based on our historical run rate of revenue and costs, assuming this customer would have otherwise generated an additional $3 million in contract manufacturing revenue during the year ended December 31, 2014, the loss of this customer is expected to result in a reduction in gross profit of approximately $0.3 million and non-absorption of up to $0.7 million in certain manufacturing overhead costs for the year ending December 31, 2014. The financial effect on the Company of this contract termination may be mitigated if the related overhead costs can be reduced or reallocated to other products, such as our existing or new core products or new contract manufacturing relationships. In contrast, we expect an increase in overall gross margin percentage related to products reflecting the reduction in materials and supplies required to manufacture the contract manufactured product.

Mike Rice commented by stating, "The contract manufacturing relationship with this customer has been a great opportunity for BioLife to utilize the excess manufacturing capacities of our best-in-class Bothell cGMP production facility. While we will continue to pursue new contract manufacturing opportunities as an important component of our business, the primary strategic focus of our resources will be to support of expansion of our core business, such as the successful launch of biologistexSM, our new cloud-based information service for controlled temperature containers for cells and tissues together with SAVSU Technologies, Inc. ("SAVSU") We are currently working with SAVSU to finalize the financial, technical and legal aspects of the biologistex product line, including whether the products will be owned and marketed by BioLife or by another entity, in which BioLife and SAVSU may hold an interest. We believe this represents a significant growth opportunity for us. biologistex is complementary with our proprietary biopreservation media products and we are now recruiting additional sales and marketing professionals to drive adoption of our entire biopreservation tools portfolio."

2014 Outlook

Management believes that awareness and adoption of the Company's products will continue to grow. In addition to the Company's NASDAQ uplisting and debt conversion which have already been achieved, specific corporate goals for 2014 include:

Proprietary, core product revenue growth in 2014 of 25%-35% over the prior year. Drive adoption of SAVSU precision thermal shippers for cells and tissues via our recently announced biologistex service. Introduction of new packaging alternatives for our biopreservation media products. Gaining additional regenerative medicine customers. Increased adoption of HypoThermosol in the hair transplantation market. The Company will host a conference call and live webcast at 4:30 p.m. ET this afternoon. To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at www.biolifesolutions.com. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 43687830. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolutions.com for 90 days.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning our 2014 outlook, potential revenue growth and market expansion, new products and customers, the potential benefits of our NASDAQ listing, and the timing and potential consequences of the termination of our agreement with ORS and the related tail period provisions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of our products; market volatility; competition; litigation; uncertainty regarding our ability to reduce or reallocate overhead expenses related to ORS; the need to negotiate and execute definitive agreements with SAVSU Technologies, Inc., in order to proceed with the planned biologistex product line; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Senior Vice President, Chief Financial Officer

Three Month Period Ended March 31,

Amortization of deferred financing costs

Basic and diluted net loss per common share

Basic and diluted weighted average common shares used to calculate net loss per common share

Promissory notes payable, related parties

Accrued interest, related parties

Total shareholders' equity (deficiency)

Three Months Ended

March 31,

Cash used in operating activities

Cash used in investing activities

Cash provided by financing activities

Net increase (decrease) in cash and equivalents

SOURCE BioLife Solutions, Inc.

RELATED LINKS
http://www.biolifesolutions.com

reade more...

Biometric Company NXT-ID, Inc. Announces Limited Edition Wocket™ to Shareholders of Record May 23, 2014

SHELTON, Conn., May 1, 2014 /PRNewswire/ -- NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, reports it is offering a limited edition "Signature" Wocket smart wallet to its shareholders. Wocket™ is a next generation smart wallet, designed to replace all the cards in your wallet.

The company also announces that the retail pricing for Wocket will be $149.99.

Mr, Gino Pereira, CEO of NXT-ID, Inc. said , "Shareholders of record owning 100 shares or more as of May 23rd, 2014 that advance order, and pay for, a Wocket on the website www.wocketwallet.com between May 28th and June 15th, 2014 will be issued a special limited "Signature" edition Wocket."

NXT-ID is currently launching a marketing campaign for its smart wallet, Wocket™, which is designed to protect your identity and replace all the cards in your wallet, no smart phone required. A series of CNBC ads will start airing during prime-time hours commencing the week of May 12th, followed by a press conference and marketing event for media and shareholders May28th at the Plaza Hotel in New York. Advance ordering will be available online following the event. Additional marketing will include online and print ads for Wocket's launch.

"Some of the largest, most successful companies have implemented similar opportunities to share the benefits of their companies with their shareholders. This is a way for us to thank our shareholders that believe in our next generation technology," said Gino Pereira, CEO of NXT-ID, Inc. "We believe can change the whole wallet industry. The wallet is the last bastion of the pre-digital age. We intend to change that by providing a modern smart wallet that is both comfortable and convenient to use, all the while protecting your identity and assets; it's your personal vault."

Media and shareholders wishing to attend the May 28th Plaza Hotel event ( from 3:00 to 5:00 P.M.) can email info@nxt-id.com and request to be added to the limited guest list.

Interested consumers can also sign up for product info and news alerts in anticipation of the product. Advance ordering will be available following the May 28th event at http://www.wocketwallet.com/

The Wocket product FAQ is available to consumers and media at http://nxt-id.com/wocket-faq/

About NXT- ID Inc. - Mobile Security for a Mobile World

NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.wocketwallet.com/

NXT-ID's wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, the Company's securities.

Forward-Looking Statements for NXT-ID

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Contact:

Corporate info: info@nxt-id.com

Investor Inquiries:

Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com

Media: 800 665-0411

SOURCE NXT-ID, Inc.

Biometric Company NXT-ID, Inc. Announces CNBC Ad Campaign for Wocket™, its Next Generation Smart Wallet, to Start in May

SHELTON, Conn., April 16, 2014 /PRNewswire/ -- NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, announced today that it will be featuring its next generation smart wallet, Wocket™, designed to replace all the cards in your wallet in a CNBC ad campaign starting in May. The add roll-out will commence prior to the previously announced May 28th press conference and marketing event to held at the Plaza Hotel in New York City.

The ad campaign will focus on Wocket™'s launch and its potential to revolutionize the payment industry.

Wocket™ is a smart wallet in the same vein as the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices. Wocket™ is a next generation smart wallet designed to replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.

Mr. Gino Pereira, CEO of NXT-ID, Inc. said in regards to the upcoming ad campaign, "According to Travelers Insurance Company, 44% of all identity theft in the United States stems from a lost or stolen wallet. Approximately 12 million people a year fall victim to identity fraud. Wocket™ is the solution to this epidemic. Wocket replaces your existing wallet and stores all the cards that you own in a secure environment and utilizes one dynamic card to represent all your cards."

Starting dates and air times for the ad campaign on CNBC will be announced shortly. The May 28th event will introduce Wocket™, its new brand identity and marketing roll out.

Media and shareholders wishing to attend the May 28th event can email info@nxt-id.com.

Wocket Consumer FAQ:

"What is Wocket ™?

Wocket™ is a smart wallet. Like the smart phone and smart watch, NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices.

"What does Wocket™ do?

Wocket™ locks all of your private information in an electronic "vault", where only an authenticated owner can authorize access to the data. Thus, you can "lock it with Wocket™ in your pocket", protecting your private information from unauthorized access.

"What makes Wocket™ smart?

Wocket™ smart wallet protects all of your private information inside an electronic vault while reducing the number of cards in your wallet. Dynamic pairing for authentication and encrypted data transfer with other secondary devices along with a plethora of new, innovative features makes Wocket™ the smartest wallet ever devised.

"How is Wocket™ different from other smart card solutions?

Wocket™ is not a smart card - it is a smart wallet. Thus, it can communicate with smart cards, but is not limited in the number, type, or method of communication of private information that typically restricts the use of a smart card. Furthermore, Wocket™ is not dependent on proximity or any other external factors to secure and choose soft-cards containing private information.

"How is Wocket™ different from other digital wallet solutions?

Rather than replace a wallet as many "digital wallet" technologies attempt to do, we chose to improve the wallet. Unlike other digital wallet solutions that depend on connectivity to choose a payment account, Wocket™ does not depend upon the cloud to select or make a payment.

"Does Wocket™ require another device, such as a cell phone?

No. Although Wocket™ does not require any other peripheral for security or "proximity sensing", Wocket™ can authenticate with secondary devices prior to transaction as an additional step in security as well as utilize a Wocket™ app on other devices to select or manage a soft-card, all without revealing private information.

"How do I access my private information?

A combination of biometrics, personal PIN or pattern provides multi-factor security for your Wocket™. Once Wocket™ verifies your identity, you can simply select whatever soft-card or information you want from the touch screen display, or in some configurations, your voice command.

"How many cards can be securely stored on a Wocket™?

Up to 10,000 cards, records, coupons, etc. and up to 100 voice commands can also be stored on Wocket™. More can be supported with optional additional memory.

The full Wocket product FAQ is available to consumers and media at
http://nxt-id.com/wocket-faq/.

Interested consumers can also sign up for product info and news alerts in anticipation of the product. Pre-ordering will be available following the May 28th event. http://www.thewocket.com/, http://www.wocketwallet.com/

About NXT-ID, Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/, http://www.wocketwallet.com/

NXT-ID's wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/

Contact:

Corporate info: info@nxt-id.com

Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com

Media: 800 665-0411

SOURCE NXT-ID, Inc.

RELATED LINKS
http://www.nxt-id.com
http://www.thewocket.com

reade more...

AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer

NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial will compare patients randomized to receive either the standard chemotherapies of carboplatin and paclitaxel with the addition of veliparib, versus patients receiving carboplatin and paclitaxel with the addition of placebo.

"Lung cancer is one of most common cancers worldwide and can be difficult to treat, particularly when it is diagnosed in the more advanced stages of the disease," said Scott Brun M.D., vice president, Pharmaceutical Development, AbbVie. "This Phase III trial is an important step in the development of veliparib and in potentially providing patients with squamous non-small cell lung cancer with a new treatment option."

This randomized, placebo-controlled, double-blind, multicenter, Phase III trial will recruit approximately 900 patients. The primary efficacy outcome of the trial is overall survival (OS). Other pre-specified outcome measures include progression-free survival (PFS), and objective response rate (ORR). The safety of veliparib will also be evaluated in the trial.

More information on the trial is available at www.clinicaltrials.gov (NCT02106546).

About Veliparib (ABT-888)
Veliparib (ABT-888) is an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor being evaluated in multiple tumor types. PARP is a naturally occurring enzyme in the body that repairs damage to DNA, and contributes to chemotherapy resistance in cancer cells. Discovered and developed by AbbVie researchers, veliparib is being developed to increase the effectiveness of common DNA-damaging therapies like chemotherapy or radiation. Veliparib is currently being studied in more than a dozen cancers and tumor types, including breast, ovarian, and non-small cell lung cancers.

About Non-Small Cell Lung Cancer (NSCLC)
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85-to-90 percent of diagnosed cases.i There are three common subtypes of NSCLC: adenocarcinoma, squamous cell (epidermoid) carcinoma, and large cell (undifferentiated) carcinoma. Adenocarcinoma accounts for approximately 40 percent of lung cancers and is the most common form of NSCLC in patients who smoke, have smoked or have never smoked. Adenocarcinoma typically originates in the outer parts of the lung. Squamous cell carcinoma accounts for about 25-to-30 percent of NSCLC cases, and is usually found in the middle airways of the lungs. Squamous cell is often linked to patients with a history of smoking. About 10-to-15 percent of NSCLC cases are considered large cell carcinomas, which tend to grow and spread quickly, making it a more difficult-to-treat form of NSCLC. Other subtypes exist, but are less common.ii

Lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women. It accounts for about 13 percent of all new cancers in the U.S. and is the leading cause of cancer-related death among both men and women, causing more deaths than colon, breast, and prostate cancers combined.iii Worldwide, it is the most common form of cancer.iv Once NSCLC is diagnosed, treatment options can include surgery, radiation therapy, chemotherapy or targeted therapies, depending on the stage of the disease.v

About AbbVie Oncology
The fight against cancer is one of the greatest battles in medicine and the varied nature of the disease requires a diverse approach that looks at multiple disease targets in a variety of tumor types. AbbVie's oncology research is focused on the discovery and development of targeted therapies that work against the processes cancers need to survive. By investing in new technologies and approaches, we are breaking ground in some of the most widespread and difficult-to-treat cancers, including multiple myeloma and chronic lymphocytic leukemia. Our oncology pipeline includes multiple new molecules in clinical trials being studied in more than 15 different cancers and tumor types.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

i "Non-Small Cell Lung Cancer." The American Cancer Society, Accessed March 12, 2014: http://www.cancer.org/cancer/lungcancer-non-smallcell/index?sitearea

ii "Non-Small Cell Lung Cancer: Detailed Guide." The American Cancer Society, Accessed March 12, 2014: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/index

iii "What Are the Key Statistics About Lung Cancer?" The American Cancer Society, Accessed March 12, 2014: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics

iv "Lung Cancer Incidence Statistics." Cancer Research U.K., Accessed March 12, 2014: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/incidence/uk-lung-cancer-incidence-statistics#geog

v "What Are the Key Statistics About Lung Cancer?" The American Cancer Society, Accessed March 12, 2014: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-treating-general-info

SOURCE AbbVie

GenomeDx Biosciences Announces data on genomic tests for prostate and bladder cancer to be presented at the annual meeting of UAE

SAN DIEGO, 11 April 2014/PRNewswire /-GenomeDx Biosciences announced today two study abstracts for Genomic analysis of the company for the prostate and bladder cancers have been chosen as "Best posters in a Poster Session" by the organizers of the Conference in the annual European Congress 29 Association of Urology.

The first presentation of poster shows the clinical validation of decipher sorter ® for prostate cancer for the prediction of failure of treatment in men treated with radiation therapy after surgery. The second poster presentation, reports on the discovery and validation of a genomic signature 15-marker to predict recurrence of high-risk bladder cancer.

Follow the timetable for the presentation of posters in UAE:

Session title: "Improvement in the measurement of biomarkers in prostate cancer"
Overview of title: "Validation of a classifier of genomic for prediction of biochemical failure after postoperative radiotherapy in high-risk prostate cancer"
Date and time: Saturday, April 12, 2014, 16:00 to 17:30 UTC
Room: A2
Abstract #: 205

Session title: "Modern staging in bladder and upper tract urothelial carcinomas: a new era has begun"
Overview of title: "Discovery and validation of a signature of novel expression for prediction of recurrence in subsequent cystectomy of high-risk bladder cancer"
Date and time: Monday, April 14, 2014, 12:15 to 13:45 UTC
Room: K1
Abstract #: 898

About GenomeDx Biosciences
GenomeDx Biosciences develops and markets Genomic analysis for prostate and other Urologic Cancers that impact treatment decisions, improve patient outcomes and ultimately reduce health care costs. GenomeDx has developed the decoding of prostate cancer classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer regardless of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. www.genomedx.com

Press contact:
Cammy Duong
Canale communications
619-849-5382
Cammy@canalecomm.com

SOURCE GenomeDx Biosciences

Biophotonics Conference and Exhibition strategies Announces speakers

PennWell Corp. is a business-to-business communication and information media diversified company that provides quality content and integrated marketing solutions for the following industries: electricity, water and wastewater, oil and gas, renewable,... jwplayer. key = ' 2k?/GKwZ2uQZmDlQ9VYArfZt2b4 + KhHX3 + DM4zisgtE = ";NASHUA, New Hampshire, 10 April 2014/PRNewswire /-strategies in Biophotonics Announces speakers for the meeting in Boston, September 9-11. This new Conference with exhibition brings together an outstanding group of rapporteurs who have been involved in the development and marketing of products based on optics and Photonics and biomedical technologies.

Speakers include:

Robert S. Langer, Professor of ScD, MIT Institute, whose patents have been approved by more than 250 pharmaceutical, chemical, biotechnology and medical devices: creation and implementation of advanced technologies. David Walt, PhD, Tufts and HHMI Professor and co-founder of Illumina, the first sequencing of the DNA of the company to achieve the genome $1000: lessons learned from taking discoveries from the academic laboratory through marketing. Ellen Strahlman,MD, Corporation, Senior Vice President of R & D and Chief Medical Officer at BD Biosciences: meeting market needs with innovation. Gregory Altshuler, PhD, DSc, Senior Vice President of R & D at the Palomar Medical: creation of new products for life science markets.In addition, well-known leaders in their fields will address issues ranging from the role of optics and Photonics in the life science market to global opportunities in the trends towards the point of care and mobile health services.

These speakers are:

Robert Alfano, PhD, Director of the Institute for ultrafast spectroscopy & laser, City College of the city of New York, referring to the light advances in biomediphotonics Anita Goel, MD, PhD, CEO of Nanobiosym and winner of the Nokia XChallenge, talks about personalized medicine and global health Robert Nordstrom, PhD, Program Director of the program of the NIH cancer imaging, speaking in translating ideas Biophotonics in commercial utility Joseph SchmittPhD, Vice President of development advanced in St. Jude Medical, talking about the marketing diagnosis, Amy Kerdok, PhD, Director of development at Intuitive Surgical clinical engineering, discusses lessons learned optical integrator in surgical robots Myron Greenspan, lawyer of Lackenbach Siegel LLP, about what you should know about property intellectual and patent law two panels innovative experts:

Fabian d ' Souza, MD, President of Boston partners, leads a discussion with physicians, including John Frangioni, MD and Penny Ford-Carleton, RN, MS, meet your requirement with heads of John Dexheimer, counsel to the President of LightWave, optical technologies and photonics, a group of investors to provide knowledge on financing and acquisition strategies "are very excited to have such distinguished speakers from a through a variety of doctors and fields of technology of the Academy", business, finance and Government, "said Barbara Goode, co-Chair of the Conference and Editor in Chief of the BioOptics World."I think that assistants are valuable resources and knowledge, as we combine a truly unique and diverse group of people who are involved in the development and commercialization of Biophotonics-based products that are revolutionizing the Sciences of life."

Strategies in Biophotonics Conference and Exhibition is the only event dedicated to enable successful market and product development of biomedical technologies and products based on optics and photonics. It will be held at the Boston Park Plaza Hotel from 9 to 11 September 2014.

The event is owned and produced by PennWell and is organized by BioOptics and Laser Focus world. To register online and to learn more about strategies in Biophotonics, visit: www.strategiesinbiophotonics.com.

About PennWell
PennWell Corp. It is a business-to-business communication and information media diversified company that provides quality content and solutions for the following industries of integrated marketing: optoelectronics, fiber optics, electric power, water and wastewater, oil and gas, renewable, electronics, semiconductors, control of pollution, enterprise storage, convert, nanotechnology, fire, emergency services and dental. Founded in 1910, PennWell publishes over 100 print and online magazines and newsletters, performs 60 conferences and exhibitions on six continents and has a wide range of books, maps, web sites, research and database services. In addition to PennWell in Tulsa, Oklahoma, headquarters the company has main offices in Nashua, New Hampshire; Houston, Texas; London, England; Mountain View, California; Fairlawn, New Jersey, Moscow, Russia and Hong Kong, China. In 2010, PennWell celebrates 100 years in business.

Contact:
Amanda Brumby
Marketing manager
Amandab@PennWell.com
352-804-9091

Logo - http://photos.prnewswire.com/prnh/20110627/DA26630LOGO

SOURCE PennWell Corp.

Secure Identity & Biometrics Association (SIBA) Announces Its Board of Directors, Comprised of the Very Best in Commercial and Strategic Leadership and Identity Expertise

Janice Kephart, SIBA founder and CEO. (PRNewsFoto/Secure Identity & Biometrics Association)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";WASHINGTON, April 9, 2014 /PRNewswire/ -- The Secure Identity & Biometrics Association (SIBA), a non-profit association established in February 2014 to encourage use of solutions that protect and secure identity across private and public platforms, today announces its board members. The new SIBA board represents proven expertise in identity management and biometric solutions, high technology government relations and commercialization, and the defense, intelligence and homeland security communities. "I am so pleased with the diverse and highly relevant experience on the SIBA board," said Janice Kephart, SIBA CEO. "We are already covering new thought leadership ground on the most pressing secure identity and biometric issues, and with a board like this, we will have the ability to reach audiences in business, government and consumer level in a manner unprecedented to date."

Photo - http://photos.prnewswire.com/prnh/20140409/PH01124-a

Logo - http://photos.prnewswire.com/prnh/20140409/PH01124LOGO-b

SIBA board members are:

Jim Annulis, President and CEO, ProQual-I.T., Inc. Ernest Baynard, President, Meridian Hill Strategies Inc. Michael Dougherty, Director of Law Enforcement Solutions, Raytheon Lester Quintana, Senior Vice President, Cellucci Associates Paul Schuepp, President and CEO, Animetrics Matthew Young, Manager, Biometric and Identity Intelligence Solutions, Sotera Defense SolutionsSIBA strategic advisors are:

Reed Stager, President, Five Peaks Group Horace Kephart, former President and CEO, G.O. Carlson Inc. Paul Schuepp and Jim Annulis said this about serving on the SIBA board:

"Animetrics enthusiastically joined SIBA as a founding member. Janice Kephart's timing establishing SIBA, with the current tsunami of activity and demand for the biometric industry and technology providers, was a perfect opportunity for Animetrics to play a significant role in our industry's advocacy and thought leadership. SIBA has created the forum for responsible industry organizations to participate in creation of consensus, economic security, policy and legislative change." - Paul Schuepp

"Being an entrepreneur, I realize that novel concepts keep business and technology moving forward - to challenge the status quo, enabling better ideas to root and flourish. That's not easy to do, but it's necessary. After my first discussion with Janice Kephart, it was evident that she possessed what I consider to be the three necessary characteristics of a change agent: knowledge, influence, and guts. With Janice at SIBA's helm, I think we can introduce new identity management solutions and help people understand how those solutions can improve their lives." - Jim Annulis

Ernest Baynard states: "The global identity management and biometrics community is at a critical crossroads right now with new use cases launching worldwide while decision makers here in the United States continue to make critical decisions regarding the use of new technologies here at home. It is essential that, as a nation, we get this right on both the facts and the policy -- I am confident that SIBA will provide an impactful and insightful voice to this important debate."

Emerging technology and commercialization strategist Dr. Thomas Cellucci, Ph.D., MBA Chairman & CEO of Cellucci Associates, Inc., says of SIBA's potential: "As one who frequently works with the intelligence community, I see great value in the next generation of biometric and identity systems that provide innovation." Cellucci is author of the best seller An Innovative Guide to Public-Private Partnerships. Lester Quintana's view: "Biometrics and identity management are at the core of emerging technologies for all sectors, including global markets. Cellucci Associates believes SIBA is the forum to provide the essential leadership in a dynamic market."

Matthew Young approaches SIBA from the perspective of technology integration and interoperability. "SIBA is well positioned to enable the biometrics industry to integrate into the commercial and government sectors by bringing together SMEs, business leaders, and expertise in legal and policy implications. SIBA has a key responsibility to provide sufficient awareness and information for decision makers and consumers alike, allowing them to determine the appropriate role for biometric and identity technology."

SIBA is a group of vendors and other stakeholders with a common interest in proactive thought leadership, communications and government relations. Its mission is to create awareness and promote the value of secure identity technologies and biometric solutions that effectively protect and secure individuals from identity threats as well as protect and secure facilities, organizations and governments.

For more on SIBA CEO Janice Kephart, see the press release announcing SIBA's establishment here.

http://www.sibassoc.org

Contact:
Janice Kephart
703-581-7721

Read more news from Secure Identity and Biometrics Association.

SOURCE Secure Identity & Biometrics Association

Secure Identity & Biometrics Association (SIBA) Announces Its Board of Directors, Comprised of the Very Best in Commercial and Strategic Leadership and Identity Expertise

Photo - http://photos.prnewswire.com/prnh/20140409/PH01124-a

Logo - http://photos.prnewswire.com/prnh/20140409/PH01124LOGO-b

SIBA board members are:

Reed Stager, President, Five Peaks Group Horace Kephart, former President and CEO, G.O. Carlson Inc. Paul Schuepp and Jim Annulis said this about serving on the SIBA board:

For more on SIBA CEO Janice Kephart, see the press release announcing SIBA's establishment here.

http://www.sibassoc.org

Contact:
Janice Kephart
703-581-7721

Read more news from Secure Identity and Biometrics Association.

SOURCE Secure Identity & Biometrics Association

Bruin Biometrics announces SEM Scanner™ and the 'sixth vital sign' to assess pressure ulcers

BBI Logo. (PRNewsFoto/Bruin Biometrics, LLC)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SOUTHAMPTON, England, March 27, 2014 /PRNewswire/ -- 2nd EPUAP Focus Meeting on Skin Health and the Microclimate, University of Southampton -- Bruin Biometrics, LLC ("BBI"), a biometric sensing medical device company today announced significant clinical breakthroughs in the assessment of pressure ulcers using BBI's SEM Scanner™, a CE marked medical device.

Bruin Biometrics will present these data in detail during a two-week EU clinical and policy presentation series under the theme, "Making Pressure Ulcer Prevention Possible," between March 31 and April 11, 2014, including a presentation at the 2nd Focus Meeting of the EPUAP April 7 – 9, 2014.

"We are living through a healthcare transformation that holds the promise of sparing millions of patients from unnecessary pain and potential early mortality. Policy makers across Europe, many of whom consider pressure ulcers to be unacceptable quality events, have crafted and are implementing policies that are increasingly holding healthcare providers financially responsible for the billions of Euro required to treat pressure ulcers," said Martin Burns, CEO of Bruin Biometrics. "The SEM ScannerTM is coming to market, with breakthrough clinical data, at a critical time for healthcare systems and aging populations."

Interim results from BBI's clinical studies show statistically significant SEM ScannerTM readings from patients with confirmed Stage I ulcers, as well as Deep Tissue Injury (DTI). Three clinical breakthroughs have thus far been observed:

SEM readings at the center of a sacral pressure ulcers, where compromised tissue is present, are significantly lower than readings at the periphery of the pressure ulcer; Around the periphery of the pressure ulcers, SEM readings converge toward those observed over vascularized, viable tissue as indicated by control site readings obtained from subjects' sternums; and, SEM readings at the center of existing sacral pressure ulcers are statistically different from SEM readings at the sacra in a population at risk for pressure ulcers and in healthy subjects.These data patterns have been independently observed in subjects across two separate study sites under the auspices of two autonomous principal investigators.

"These data hold tremendous clinical and economic value for practitioners assessing patients at admission, at discharge and during stay for the existence of pressure ulcers and deep tissue injuries," Burns said.

The current standard of care in pressure ulcer prevention is based on visual assessment, which focuses on areas where pressure ulcers most commonly develop: sacra and heels, for example. Unfortunately, the quality of visual skin inspection is highly dependent on the skill of the caregiver, and wide and varying results occur. By the time pressure-induced tissue damage is visually evident at the skin's surface, significant damage has already occurred.

The SEM Scanner can be used by all healthcare practitioners. And SEM Scanner readings – the 6th vital sign – are readily interpreted and tracked. The device uses integrated sensor technology to assess inflammatory changes associated with pressure-induced tissue damage.

"Pressure ulcers can be aggressively addressed as a problem if healthcare workers use the SEM ScannerTM as a part of their vital signs checks," Burns said. "Pressure ulcer scanning should be the sixth vital sign check of all at risk patients."

About Bruin Biometrics

Bruin Biometrics (BBI) is relentlessly committed to using technology to improve the way that health care is delivered. By developing innovative biometric medical device systems that can cost-effectively detect and monitor select medical conditions with urgent clinical need, BBI is helping inform clinical decisions, simplify patient care, and improve patient outcomes. BBI has developed the SEM ScannerTM, a revolutionary wound information medical device to detect the inflammatory changes associated with pressure induced tissue damage. BBI's second product, the OrthoSonosTM is an innovative medical device to detect and monitor the health of native joints and prosthetic implants. Neither SEM ScannerTM nor OrthoSonosTM are currently approved by the FDA for sale in the United States. The SEM ScannerTM has been CE Marked and is currently in full commercial launch in geographies recognizing CE Marking. OrthoSonosTM is on track for commercial launch in early 2015. To learn more about BBI please visit www.bruinbiometrics.com.

Logo - http://photos.prnewswire.com/prnh/20131018/LA00429LOGO

SOURCE Bruin Biometrics, LLC

RELATED LINKS
http://www.bruinbiometrics.com

reade more...

Bruin Biometrics announces SEM Scanner™ and the 'sixth vital sign' to assess pressure ulcers

About Bruin Biometrics

Logo - http://photos.prnewswire.com/prnh/20131018/LA00429LOGO

SOURCE Bruin Biometrics, LLC

RELATED LINKS
http://www.bruinbiometrics.com

reade more...

Pages

.